Nexus BioPharma, Inc., a Nevada corporation  (OTC-BB NEXS), formerly Plata Resources, Inc. (OTCBB: PTAE) announced, that effective June 10, 2016, it completed a merger with Nexus BioPharma, Inc., a life science company focused on developing and commercializing a proprietary drug to treat obesity. In connection with the transaction, the Company received 100% of the issued and outstanding shares of common stock of Nexus, which became the wholly-owned operating subsidiary of the Company.

"The completion of this merger and share exchange marks a major milestone in the progression of Nexus being able to continue successful research and development of our weight loss drug candidate," said Mr. Warren C. Lau, Chief Executive Officer and President of the Company. Mr. Lau continued "As an operating public company, we will have greater access to the capital markets, enabling us to complete the drug optimization and pre-IND studies necessary to progress to FDA human trials."

The Company intends to file a Form 8-K with the Securities and Exchange Commission that will include information regarding the merger and providing detailed information regarding the business of Nexus.

About Nexus BioPharma, Inc. www.nexusbiopharma.com

At Nexus BioPharma, Inc. we are developing a weight loss drug that activates the AMPK metabolic pathway, the same pathway activated by intense physical exercise.